Search results for "Parkinson’S disease"

showing 10 items of 90 documents

Vitamin D and Parkinson's Disease.

2022

Vitamin D is a fat-soluble secosteroid, traditionally considered a key regulator of bone metabolism, calcium and phosphorous homeostasis. Its action is made possible through the binding to the vitamin D receptor (VDR), after which it directly and indirectly modulates the expression of thousands of genes. Vitamin D is important for brain development, mature brain activity and associated with many neurological diseases, including Parkinson’s disease (PD). High frequency of vitamin D deficiency in patients with Parkinson’s disease compared to control population was noted nearly twenty years ago. This finding is of interest given vitamin D’s neuroprotective effect, exerted by the action of neur…

125-dihydroxyvitamin DDisease progressionNutrition and DieteticsParkinson DiseaseVitaminsVitamin D DeficiencyNeuroprotectionCalcium DietaryParkinson’s diseaseHumansSettore MED/26 - NeurologiaNeurodegenerationVitamin DHumanFood ScienceNutrients
researchProduct

Common miRNA Patterns of Alzheimer's Disease and Parkinson's Disease and Their Putative Impact on Commensal Gut Microbiota.

2019

With the rise of Next-Generation-Sequencing (NGS) methods, Micro-RNAs (miRNAs) have achieved an important position in the research landscape and have been found to present valuable diagnostic tools in various diseases such as multiple sclerosis or lung cancer. There is also emerging evidence that miRNAs play an important role in the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease (AD) or Parkinson’s disease (PD). Apparently, these diseases come along with changes in miRNA expression patterns which led to attempts from researchers to use these small RNA species from several body fluids for a better diagnosis and in order to observe disease progression. Additionally, it…

610 Medical sciencesmicro-RNAsneurodegenerationParkinson’s disease610 Medizingut microbiomeAlzheimer’s diseaselcsh:Neurosciences. Biological psychiatry. NeuropsychiatryNeuroscienceOriginal Researchcrosstalklcsh:RC321-571Frontiers in neuroscience
researchProduct

Age at menopause predicts age at onset of Parkinson's disease.

2006

We investigated the association between age at onset of Parkinson's disease (PD) and fertile life characteristics in 145 women. Linear regression analyses showed a significant correlation between age at PD onset and age at menopause (P = 0.003), between age at PD onset and fertile life duration (P = 0.008), and a nonsignificant correlation between PD onset and cumulative duration of pregnancies (P = 0.23). These results support the possible role of estrogens in PD.

AdultAgingmedicine.medical_specialtyParkinson's diseasePhysiologyDiseaseRisk AssessmentCentral nervous system diseaseDegenerative diseasefertile lifePregnancyRisk FactorsInternal medicineage at menopausemedicineHumansAge of OnsetRisk factorAgedAged 80 and overPregnancybusiness.industryParkinson DiseaseMiddle Agedmedicine.diseaseMenopauseEndocrinologyNeurologyParkinson’s diseaseLinear ModelsSettore MED/26 - NeurologiaFemalewomenNeurology (clinical)MenopauseAge of onsetbusiness
researchProduct

Executive functioning and serum lipid fractions in Parkinson’s disease—a possible sex-effect: the PACOS study

2022

AbstractThe association between dyslipidemia and cognitive performance in Parkinson’s disease (PD) patients still needs to be clarified. Aim of the study was to evaluate the presence of possible associations between serum lipids fractions and executive dysfunction also exploring the sex-specific contribute of lipids level on cognition. Patients from the PACOS cohort, who underwent a complete serum lipid profile measures (total cholesterol-TC, low-density lipoprotein cholesterol-LDL, high-density lipoprotein cholesterol-HDL and triglycerides-TG) were selected. Adult Treatment Panel III guidelines of the National Cholesterol Education Program were used to classify normal/abnormal lipid fracti…

AdultMaleCholesterol HDLParkinson DiseaseCholesterol LDLMiddle AgedLipidsExecutive functionsPsychiatry and Mental healthCholesterolNeurologyParkinson’s diseaseHumansFemaleSettore MED/26 - Neurologialipids (amino acids peptides and proteins)Neurology (clinical)TriglyceridesBiological PsychiatryAgedJournal of Neural Transmission
researchProduct

Urological dysfunctions in patients with Parkinson’s disease: clues from clinical and non-invasive urological assessment

2018

Abstract Background Autonomic nervous system dysfunction, common in patients with Parkinson’s disease (PD), causes significant morbidity and it is correlated with poor quality of life. To assess frequency of urinary symptoms in patients with PD, without conditions known to interfere with urinary function. Methods Non-demented PD patients were consecutively enrolled from the outpatients clinic of our department. Scales investigating motor and non-motor symptoms were carried out. Evaluation of urinary dysfunctions was carried out using the AUTonomic Scale for Outcomes in Parkinson’s disease (SCOPA-AUT) questionnaire. Patients underwent noninvasive urological studies (nUS), including uroflowme…

AdultMaleUrologic Diseasesmedicine.medical_specialtyNeurologyParkinson's diseaseUrinary systemAutonomic dysfunction030232 urology & nephrologyNon-motor symptomsUrinary symptomsDiseaseNon-motor symptomlcsh:RC346-429SCOPA-AUT03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesInternal medicinemedicineHumansNeurochemistryStage (cooking)lcsh:Neurology. Diseases of the nervous systemAgedbusiness.industryAUTonomic SCale for outcomes in Parkinson’s diseaseParkinson DiseaseGeneral MedicineMiddle AgedUrinary functionmedicine.diseaseAutonomic Nervous System DiseasesQuality of LifeParkinson’s diseaseFemaleSettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusiness030217 neurology & neurosurgeryBMC Neurology
researchProduct

Pain perception in Parkinson's disease: A systematic review and meta-analysis of experimental studies

2017

While hyperalgesia (increased pain sensitivity) has been suggested to contribute to the increased prevalence of clinical pain in Parkinson's disease (PD), experimental research is equivocal and mechanisms are poorly understood. We conducted a meta-analysis of studies comparing PD patients to healthy controls (HCs) in their response to experimental pain stimuli. Articles were acquired through systematic searches of major databases from inception until 10/2016. Twenty-six studies met inclusion criteria, comprising 1292 participants (PD = 739, HCs = 553). Random effects meta-analysis of standardized mean differences (SMD) revealed lower pain threshold (indicating hyperalgesia) in PD patients d…

Agingmedicine.medical_specialtyParkinson's diseaseDopamineAnalgesicDopaminaStimulationDiseaseBiochemistry03 medical and health sciences0302 clinical medicinesystematic reviewDopamineInternal medicineThreshold of painmedicineHumanspain030212 general & internal medicineMolecular Biologybusiness.industryPain PerceptionParkinson DiseaseParkinson’s disease Dopamine Pain Meta-analysis Systematic reviewmedicine.diseasemeta-analysisNeurologyHyperalgesiaMeta-analysisHyperalgesiaPhysical therapyParkinson’s diseaseDoença de Parkinsonmedicine.symptomdopaminebusiness030217 neurology & neurosurgeryBiotechnologymedicine.drug
researchProduct

Cholesterol facilitates interactions between α‐synuclein oligomers and charge‐neutral membranes

2015

AbstractOligomeric species formed during α-synuclein fibrillation are suggested to be membrane-disrupting agents, and have been associated with cytotoxicity in Parkinson’s disease. The majority of studies, however, have revealed that the effect of α-synuclein oligomers is only noticeable on systems composed of anionic lipids, while the more physiologically relevant zwitterionic lipids remain intact. We present experimental evidence for significant morphological changes in zwitterionic membranes containing cholesterol, induced by α-synuclein oligomers. Depending on the lipid composition, model membranes are either unperturbed, disrupt, or undergo dramatic morphological changes and segregate …

AmyloidParkinson's diseaseFluorescent DyeBiophysicsPlasma protein bindingBiochemistryOligomerProtein Structure SecondaryMultiphoton microscopyMembrane phase separationCell membranechemistry.chemical_compoundGeneticStructural Biology2-NaphthylamineLaurdan fluorescenceGeneticsFluorescence microscopemedicineMolecular BiologyFluorescent DyesLaurateα-SynucleinMembranesChemistryMedicine (all)2-NaphthylamineCell MembraneMembraneCell BiologySettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)CholesterolMembranemedicine.anatomical_structureBiophysicBiochemistryStructural biologyOligomeralpha-SynucleinParkinson’s diseaseProtein MultimerizationLaurdanLauratesProtein BindingFEBS Letters
researchProduct

Driving impairment and crash risk in Parkinson disease: A systematic review and meta-analysis

2018

ObjectivesTo provide the best possible evidence base for guiding driving decisions in Parkinson disease (PD), we performed a meta-analysis comparing patients with PD to healthy controls (HCs) on naturalistic, on-the-road, and simulator driving outcomes.MethodsSeven major databases were systematically searched (to January 2018) for studies comparing patients with PD to HCs on overall driving performance, with data analyzed using random-effects meta-analysis.ResultsFifty studies comprising 5,410 participants (PD = 1,955, HC = 3,455) met eligibility criteria. Analysis found the odds of on-the-road test failure were 6.16 (95% confidence interval [CI] 3.79–10.03) times higher and the odds of sim…

Automobile Drivingmedicine.medical_specialtyMEDLINECrashDiseasemeta-analysiOdds03 medical and health sciences0302 clinical medicineInternal medicinedrivingHumansMedicine030212 general & internal medicinecrashesbusiness.industryAccidents TrafficneurodegenerationParkinson DiseaseCrash riskOdds ratioDatabases Bibliographicfitness to driveConfidence intervalMeta-analysisParkinson’s diseaseNeurology (clinical)Psychomotor Disordersbusiness030217 neurology & neurosurgery
researchProduct

Effect of Foot Orthoses and Shoes in Parkinson's Disease Patients : A PRISMA Systematic Review

2021

[Abstract] Reduced plantar foot sensation, postural instability, and gait difficulties are characteristic of Parkinson´s disease patients. A systematic review was carried out to determine the effect of the different types of insoles and shoes in these patients. Several databases were used to search for relevant articles reporting Parkinson´s disease patients undergoing treatment with any type of insole and footwear. All titles and abstracts were reviewed independently by two reviewers and the available data were extracted. The study eligibility criteria were any type of experimental study that included Parkinson’s disease patients treated with any type of insole or footwear. Eight studies w…

Balancemedicine.medical_specialtyPasoParkinson's diseasePostural instabilityMedicine (miscellaneous)EquilibrioReviewControlled studiesinsolegaitFootwearInsolePhysical medicine and rehabilitationSensationmedicineFoot OrthosesGaitBalance (ability)PlantillaImportant conclusionbusiness.industryRbalancemedicine.diseaseGaitParkinson diseaseExtremitatsPodologíaCalzadoEnfermedad de ParkinsonfootwearParkinson’s diseaseMedicineSistema nerviós Malaltiesbusiness
researchProduct

Morphometric magnetic resonance imaging cortico-subcortical features in Parkinson's disease with mild cognitive impairment

2022

Background and purpose Parkinson's disease (PD) patients with cognitive impairment undergo progressive atrophy of several cortical and subcortical areas. The aim was to study the magnetic resonance imaging (MRI) morphometric features of PD patients with mild cognitive impairment (MCI). Methods Patients from the Parkinson's Disease Cognitive Impairment Study (PACOS) cohort with an available structural volumetric brain MRI and morphometric measurements of the midbrain and pons areas, middle cerebellar peduncle, superior cerebellar peduncle width and midbrain anteroposterior diameter (A-Pdiam) were included. MCI was diagnosed according to the Movement Disorder Society level II criteria. Additi…

Cerebral CortexMaleParkinson's diseaseParkinson DiseasemidbrainNeuropsychological TestsbrainstemNeurologyParkinson’s diseaseHumansmagnetic resonance imagingCognitive DysfunctionFemaleSettore MED/26 - NeurologiaNeurology (clinical)Atrophycognitive impairment
researchProduct